Peter F. Aziz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peter F. Aziz has a total of 219 co-authors. Here are the top co-authors by number of shared publications:
Elizabeth V. Saarel
St. Luke's Children's, Department of Pediatric Cardiology, Boise, ID
7 shared publicationsIqbal El-Assaad
Department of Pediatrics, Cleveland Clinic Children's, Cleveland, Ohio
6 shared publicationsSadeer G. Al-Kindi
University Hospitals Harrington Heart and Vascular Institute, University Hospitals and Case Western Reserve University, Cleveland, Ohio
6 shared publicationsIqbal El Assaad
Cleveland Clinic Children's, Department of Pediatric Cardiology and Electrophysiology, Cleveland, OH
5 shared publicationsGerard J. Boyle
Department of Pediatric Cardiology, Cleveland Clinic Children's, Cleveland, Ohio
4 shared publications- Iqbal El Assaad
Division of Cardiology and Cardiovascular Medicine, Children's Institute Department of Heart, Vascular, and Thoracic, Cleveland Clinic Children's, Cleveland, Ohio
4 shared publications
Latest Publications
- 1 December 2025
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 18 (12) , e014299
Cautionary Tales in LQTS 2: Reassuring History With Life-Threatening Arrhythmias
- 1 December 2025
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 18 (12) , e014299
Cautionary Tales in LQTS 2: Reassuring History With Life-Threatening Arrhythmias
- 1 October 2025
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 18 (5) , e004958
Age-Dependent Contributions of Rare and Common Genetic Variation in Atrial Fibrillation
BACKGROUND: Genetic variation contributes to atrial fibrillation (AF), but its impact may vary with age. The All of Us Research Program contains whole-genome sequencing of data from 100 574 adult participants with linked electronic health records. METHODS: We assessed clinical, monogenic, and polygenic associations with AF in a cross-sectional analysis, stratified by age: 60 years (n=51 659). AF was defined as ≥2 Systematized Nomenclature of Medicine-Clinical Terms codes on separate days. We identified pathogenic/likely pathogenic variants in 145 cardiac genes with dominant inheritance and calculated a previously established polygenic risk score. Adjusted for known clinical factors, multivariable analysis quantified associations between monogenic and polygenic factors and AF in each age group. RESULTS: Among 100 574 participants (mean age 59±16 years), 7811 (7.8%) had AF, while 92 763 (92%) did not. Monogenic pathogenic/likely pathogenic variants were associated with AF across all age groups, most strongly in participants aged P =0.007). In contrast, the polygenic risk score was not associated with AF in this youngest group (odds ratio, 1.0 [95% CI, 0.9–1.2]; P =0.650) but was in older groups (odds ratio 1.3 [95% CI, 1.2–1.4]; P 60 years). Clinical factors were significantly associated with AF (C-index, 0.84 [0.83–0.84]; P P <0.001). In hazard-based time-to-event analysis, monogenic variants were associated with earlier onset, whereas the polygenic risk score was not associated with age of onset. CONCLUSIONS: In this large cross-sectional study, monogenic variants were associated with AF throughout life, particularly in younger participants, whereas polygenic risk was associated with AF only in older participants. While genetic information added only marginal improvements to AF risk discrimination beyond existing clinical risk factors, monogenic variants were associated with an earlier age of onset in participants with AF.
- 1 October 2025
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 18 (5) , e004958
Age-Dependent Contributions of Rare and Common Genetic Variation in Atrial Fibrillation
BACKGROUND: Genetic variation contributes to atrial fibrillation (AF), but its impact may vary with age. The All of Us Research Program contains whole-genome sequencing of data from 100 574 adult participants with linked electronic health records. METHODS: We assessed clinical, monogenic, and polygenic associations with AF in a cross-sectional analysis, stratified by age: 60 years (n=51 659). AF was defined as ≥2 Systematized Nomenclature of Medicine-Clinical Terms codes on separate days. We identified pathogenic/likely pathogenic variants in 145 cardiac genes with dominant inheritance and calculated a previously established polygenic risk score. Adjusted for known clinical factors, multivariable analysis quantified associations between monogenic and polygenic factors and AF in each age group. RESULTS: Among 100 574 participants (mean age 59±16 years), 7811 (7.8%) had AF, while 92 763 (92%) did not. Monogenic pathogenic/likely pathogenic variants were associated with AF across all age groups, most strongly in participants aged P =0.007). In contrast, the polygenic risk score was not associated with AF in this youngest group (odds ratio, 1.0 [95% CI, 0.9–1.2]; P =0.650) but was in older groups (odds ratio 1.3 [95% CI, 1.2–1.4]; P 60 years). Clinical factors were significantly associated with AF (C-index, 0.84 [0.83–0.84]; P P <0.001). In hazard-based time-to-event analysis, monogenic variants were associated with earlier onset, whereas the polygenic risk score was not associated with age of onset. CONCLUSIONS: In this large cross-sectional study, monogenic variants were associated with AF throughout life, particularly in younger participants, whereas polygenic risk was associated with AF only in older participants. While genetic information added only marginal improvements to AF risk discrimination beyond existing clinical risk factors, monogenic variants were associated with an earlier age of onset in participants with AF.
- 6 August 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (10) , 2650-2651
Reply to “Cardiopulmonary Exercise Testing‐Guided Beta‐Blocker Dosing in Long QT Syndrome: Genotype, Methodology, and Adherence Concerns”
- 6 August 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (10) , 2650-2651
Reply to “Cardiopulmonary Exercise Testing‐Guided Beta‐Blocker Dosing in Long QT Syndrome: Genotype, Methodology, and Adherence Concerns”
- Open Access
- 26 July 2025
- Published by Wiley
Reply to – “Cardiopulmonary Exercise Testing-Guided Beta-Blocker Dosing in Long QT syndrome: Genotype, Methodology, and Adherence Concerns”
- 26 July 2025
- Published by Wiley
Open AccessReply to – “Cardiopulmonary Exercise Testing-Guided Beta-Blocker Dosing in Long QT syndrome: Genotype, Methodology, and Adherence Concerns”
- Open Access
- 14 July 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (9) , 2287-2295
Utility of Cardiopulmonary Exercise Testing in Assessing Beta‐Blocker Efficacy in LQTS: Moving Away From One‐Size‐Fits‐All
Background: Currently, there is no specific standard to assess beta blocker efficacy in long QT syndrome (LQTS).Objective: To describe our institutional experience with utilizing cardiopulmonary exercise testing (CPET) to assess for chronotropic suppression and to compare frequency of life‐threatening events (LTEs) on intentional “submaximal” treatment to those on maximal treatment.Methods: We queried our Inherited Arrhythmia Registry and identified patients with LQTS who were on “submaximal” beta blocker doses (nadolol < 0.75‐mg/kg/day & propranolol < 2 mg/kg/day) with at least 6 months follow up. Adequate beta blockade effect was defined as at least 15% decrease from maximal HR.Results: The study included 127 LQTS patients: 47% on maximal therapy, 43% on submaximal therapy, and 10% not receiving treatment. Thirty three percent of patients were on submaximal therapy due to side effects, none in patients less than 10 years of age. Baseline characteristics were similar between the groups. There was no significant difference in LTEs between maximal and submaximal therapy (8% vs. 5.4%, p = 0.72). During CPET, patients on maximal therapy were more likely to exhibit adequate chronotropic suppression (60% vs. 40%, p = 0.01). None of the patients on submaximal therapy with adequate chronotropic effect experienced LTEs during follow‐up.Conclusions: Adequate chronotropic suppression was achieved with “submaximal” beta blocker dose in 40%. Despite similar baseline risk profiles, LTEs were not significantly different in patients with submaximal versus maximal therapy. CPET may be a useful modality to devise an individualized treatment plan, especially in those who cannot tolerate the recommended guideline directed dose.
- 14 July 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (9) , 2287-2295
Open AccessUtility of Cardiopulmonary Exercise Testing in Assessing Beta‐Blocker Efficacy in LQTS: Moving Away From One‐Size‐Fits‐All
Background: Currently, there is no specific standard to assess beta blocker efficacy in long QT syndrome (LQTS).Objective: To describe our institutional experience with utilizing cardiopulmonary exercise testing (CPET) to assess for chronotropic suppression and to compare frequency of life‐threatening events (LTEs) on intentional “submaximal” treatment to those on maximal treatment.Methods: We queried our Inherited Arrhythmia Registry and identified patients with LQTS who were on “submaximal” beta blocker doses (nadolol < 0.75‐mg/kg/day & propranolol < 2 mg/kg/day) with at least 6 months follow up. Adequate beta blockade effect was defined as at least 15% decrease from maximal HR.Results: The study included 127 LQTS patients: 47% on maximal therapy, 43% on submaximal therapy, and 10% not receiving treatment. Thirty three percent of patients were on submaximal therapy due to side effects, none in patients less than 10 years of age. Baseline characteristics were similar between the groups. There was no significant difference in LTEs between maximal and submaximal therapy (8% vs. 5.4%, p = 0.72). During CPET, patients on maximal therapy were more likely to exhibit adequate chronotropic suppression (60% vs. 40%, p = 0.01). None of the patients on submaximal therapy with adequate chronotropic effect experienced LTEs during follow‐up.Conclusions: Adequate chronotropic suppression was achieved with “submaximal” beta blocker dose in 40%. Despite similar baseline risk profiles, LTEs were not significantly different in patients with submaximal versus maximal therapy. CPET may be a useful modality to devise an individualized treatment plan, especially in those who cannot tolerate the recommended guideline directed dose.
- Open Access
- 13 September 2024
- Published by BMJ in Open Heart
- Vol. 11 (2) , e002768
Predictors of spontaneous pregnancy loss in single ventricle physiology
Background: Pregnant patients with single ventricle (SV) physiology carry a high risk of spontaneous pregnancy loss (SPL), yet the clinical factors contributing to this risk are not well defined. Methods: Single-centre retrospective study of pregnant patients with SV physiology seen in cardio-obstetrics clinic over the past 20 years with chart review of their obstetric history. Patients without a known pregnancy outcome were excluded. Univariable Bayesian panel-data random effects logit was used to model the risk of SPL. Results: The study included 20 patients with 44 pregnancies, 20 live births, 21 SPL and 3 elective abortions. All had Fontan palliation except for two with Waterston and Glenn shunts. 10 (50%) had a single right ventricle (RV). 14 (70%) had moderate or severe atrioventricular valve regurgitation (AVVR). Atrial arrhythmias were present in 16 (80%), Fontan-associated liver disease (FALD) in 15 (75%) and FALD stage 4 in 9 (45%). 12 (60%) were on anticoagulation. Average first-trimester oxygen saturation was 93.8% for live births and 90.8% for SPL. The following factors were associated with higher odds of SPL: RV morphology (OR 1.72 (95% credible interval (CrI) 1.0008–2.70)), moderate or severe AVVR (OR 1.64 (95% CrI 1.003–2.71)) and reduced first-trimester oxygen saturation (OR 1.83 (95% CrI 1.03–2.71) for each per cent decrease in O2 saturation. Conclusion: Pregnant patients with SV physiology, particularly those with RV morphology, moderate or severe AVVR, and lower first-trimester oxygen saturations, have a higher risk of SPL. Identifying these clinical risk factors can guide preconception counselling by the cardio-obstetrics team.
- 13 September 2024
- Published by BMJ in Open Heart
- Vol. 11 (2) , e002768
Open AccessPredictors of spontaneous pregnancy loss in single ventricle physiology
Background: Pregnant patients with single ventricle (SV) physiology carry a high risk of spontaneous pregnancy loss (SPL), yet the clinical factors contributing to this risk are not well defined. Methods: Single-centre retrospective study of pregnant patients with SV physiology seen in cardio-obstetrics clinic over the past 20 years with chart review of their obstetric history. Patients without a known pregnancy outcome were excluded. Univariable Bayesian panel-data random effects logit was used to model the risk of SPL. Results: The study included 20 patients with 44 pregnancies, 20 live births, 21 SPL and 3 elective abortions. All had Fontan palliation except for two with Waterston and Glenn shunts. 10 (50%) had a single right ventricle (RV). 14 (70%) had moderate or severe atrioventricular valve regurgitation (AVVR). Atrial arrhythmias were present in 16 (80%), Fontan-associated liver disease (FALD) in 15 (75%) and FALD stage 4 in 9 (45%). 12 (60%) were on anticoagulation. Average first-trimester oxygen saturation was 93.8% for live births and 90.8% for SPL. The following factors were associated with higher odds of SPL: RV morphology (OR 1.72 (95% credible interval (CrI) 1.0008–2.70)), moderate or severe AVVR (OR 1.64 (95% CrI 1.003–2.71)) and reduced first-trimester oxygen saturation (OR 1.83 (95% CrI 1.03–2.71) for each per cent decrease in O2 saturation. Conclusion: Pregnant patients with SV physiology, particularly those with RV morphology, moderate or severe AVVR, and lower first-trimester oxygen saturations, have a higher risk of SPL. Identifying these clinical risk factors can guide preconception counselling by the cardio-obstetrics team.
- 13 August 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (7) , 516-530
Vigorous Exercise in Patients With Congenital Long QT Syndrome: Results of the Prospective, Observational, Multinational LIVE-LQTS Study
BACKGROUND: Whether vigorous exercise increases risk of ventricular arrhythmias for individuals diagnosed and treated for congenital long QT syndrome (LQTS) remains unknown. METHODS: The National Institutes of Health–funded LIVE-LQTS study (Lifestyle and Exercise in the Long QT Syndrome) prospectively enrolled individuals 8 to 60 years of age with phenotypic and/or genotypic LQTS from 37 sites in 5 countries from May 2015 to February 2019. Participants (or parents) answered physical activity and clinical events surveys every 6 months for 3 years with follow-up completed in February 2022. Vigorous exercise was defined as ≥6 metabolic equivalents for >60 hours per year. A blinded Clinical Events Committee adjudicated the composite end point of sudden death, sudden cardiac arrest, ventricular arrhythmia treated by an implantable cardioverter defibrillator, and likely arrhythmic syncope. A National Death Index search ascertained vital status for those with incomplete follow-up. A noninferiority hypothesis (boundary of 1.5) between vigorous exercisers and others was tested with multivariable Cox regression analysis. RESULTS: Among the 1413 participants (13% <18 years of age, 35% 18–25 years of age, 67% female, 25% with implantable cardioverter defibrillators, 90% genotype positive, 49% with LQT1, 91% were treated with beta-blockers, left cardiac sympathetic denervation, and/or implantable cardioverter defibrillator), 52% participated in vigorous exercise (55% of these competitively). Thirty-seven individuals experienced the composite end point (including one sudden cardiac arrest and one sudden death in the nonvigorous group, one sudden cardiac arrest in the vigorous group) with overall event rates at 3 years of 2.6% in the vigorous and 2.7% in the nonvigorous exercise groups. The unadjusted hazard ratio for experience of events for the vigorous group compared with the nonvigorous group was 0.97 (90% CI, 0.57–1.67), with an adjusted hazard ratio of 1.17 (90% CI, 0.67–2.04). The upper 95% one-sided confidence level extended beyond the 1.5 boundary. Neither vigorous or nonvigorous exercise was found to be superior in any group or subgroup. CONCLUSIONS: Among individuals diagnosed with phenotypic and/or genotypic LQTS who were risk assessed and treated in experienced centers, LQTS-associated cardiac event rates were low and similar between those exercising vigorously and those not exercising vigorously. Consistent with the low event rate, CIs are wide, and noninferiority was not demonstrated. These data further inform shared decision-making discussions between patient and physician about exercise and competitive sports participation. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02549664.
- 13 August 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (7) , 516-530
Vigorous Exercise in Patients With Congenital Long QT Syndrome: Results of the Prospective, Observational, Multinational LIVE-LQTS Study
BACKGROUND: Whether vigorous exercise increases risk of ventricular arrhythmias for individuals diagnosed and treated for congenital long QT syndrome (LQTS) remains unknown. METHODS: The National Institutes of Health–funded LIVE-LQTS study (Lifestyle and Exercise in the Long QT Syndrome) prospectively enrolled individuals 8 to 60 years of age with phenotypic and/or genotypic LQTS from 37 sites in 5 countries from May 2015 to February 2019. Participants (or parents) answered physical activity and clinical events surveys every 6 months for 3 years with follow-up completed in February 2022. Vigorous exercise was defined as ≥6 metabolic equivalents for >60 hours per year. A blinded Clinical Events Committee adjudicated the composite end point of sudden death, sudden cardiac arrest, ventricular arrhythmia treated by an implantable cardioverter defibrillator, and likely arrhythmic syncope. A National Death Index search ascertained vital status for those with incomplete follow-up. A noninferiority hypothesis (boundary of 1.5) between vigorous exercisers and others was tested with multivariable Cox regression analysis. RESULTS: Among the 1413 participants (13% <18 years of age, 35% 18–25 years of age, 67% female, 25% with implantable cardioverter defibrillators, 90% genotype positive, 49% with LQT1, 91% were treated with beta-blockers, left cardiac sympathetic denervation, and/or implantable cardioverter defibrillator), 52% participated in vigorous exercise (55% of these competitively). Thirty-seven individuals experienced the composite end point (including one sudden cardiac arrest and one sudden death in the nonvigorous group, one sudden cardiac arrest in the vigorous group) with overall event rates at 3 years of 2.6% in the vigorous and 2.7% in the nonvigorous exercise groups. The unadjusted hazard ratio for experience of events for the vigorous group compared with the nonvigorous group was 0.97 (90% CI, 0.57–1.67), with an adjusted hazard ratio of 1.17 (90% CI, 0.67–2.04). The upper 95% one-sided confidence level extended beyond the 1.5 boundary. Neither vigorous or nonvigorous exercise was found to be superior in any group or subgroup. CONCLUSIONS: Among individuals diagnosed with phenotypic and/or genotypic LQTS who were risk assessed and treated in experienced centers, LQTS-associated cardiac event rates were low and similar between those exercising vigorously and those not exercising vigorously. Consistent with the low event rate, CIs are wide, and noninferiority was not demonstrated. These data further inform shared decision-making discussions between patient and physician about exercise and competitive sports participation. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02549664.
- Open Access
- 23 April 2024
- Published by Elsevier in Heart Rhythm
- Vol. 21 (10) , 2053-2054
Underestimated recurrence rates after ablation for Wolff-Parkinson-White syndrome and impact on follow-up practices
- 23 April 2024
- Published by Elsevier in Heart Rhythm
- Vol. 21 (10) , 2053-2054
Open AccessUnderestimated recurrence rates after ablation for Wolff-Parkinson-White syndrome and impact on follow-up practices
- 12 July 2023
- Published by Elsevier in Heart Rhythm
- Vol. 20 (10) , 1459-1460
Conduction defects in pediatric patients with Pearson syndrome: When to pace?
- 12 July 2023
- Published by Elsevier in Heart Rhythm
- Vol. 20 (10) , 1459-1460
Conduction defects in pediatric patients with Pearson syndrome: When to pace?
- Open Access
- 28 February 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 147 (9) , 718-727
The Prevalence and Association of Exercise Test Abnormalities With Sudden Cardiac Death and Transplant-Free Survival in Childhood Hypertrophic Cardiomyopathy
Background: Hypertrophic cardiomyopathy (HCM) can be associated with an abnormal exercise response. In adults with HCM, abnormal results on exercise stress testing are predictive of heart failure outcomes. Our goal was to determine whether an abnormal exercise response is associated with adverse outcomes in pediatric patients with HCM. Methods: In an international cohort study including 20 centers, phenotype-positive patients with primary HCM who were z scores, higher resting left ventricular outflow tract gradient, and higher frequency of myectomy compared with participants with normal test results ( P P =0.005). Patients with exercise-induced ischemia were most likely to experience all-cause death or transplant (hazard ratio, 4.86 [95% CI, 1.69–13.99]), followed by those with an abnormal blood pressure response (hazard ratio, 3.19 [95% CI, 1.32–7.71]). Exercise-induced ischemia was also independently associated with lower SCD event-free survival (hazard ratio, 3.32 [95% CI, 1.27–8.70]). Exercise-induced ectopy was not associated with survival. Conclusions: Exercise abnormalities are common in childhood HCM. An abnormal exercise test result was independently associated with lower transplant-free survival, especially in those with an ischemic or abnormal blood pressure response with exercise. Exercise-induced ischemia was also independently associated with SCD events. These findings argue for routine exercise testing in childhood HCM as part of ongoing risk assessment.
- 28 February 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 147 (9) , 718-727
Open AccessThe Prevalence and Association of Exercise Test Abnormalities With Sudden Cardiac Death and Transplant-Free Survival in Childhood Hypertrophic Cardiomyopathy
Background: Hypertrophic cardiomyopathy (HCM) can be associated with an abnormal exercise response. In adults with HCM, abnormal results on exercise stress testing are predictive of heart failure outcomes. Our goal was to determine whether an abnormal exercise response is associated with adverse outcomes in pediatric patients with HCM. Methods: In an international cohort study including 20 centers, phenotype-positive patients with primary HCM who were z scores, higher resting left ventricular outflow tract gradient, and higher frequency of myectomy compared with participants with normal test results ( P P =0.005). Patients with exercise-induced ischemia were most likely to experience all-cause death or transplant (hazard ratio, 4.86 [95% CI, 1.69–13.99]), followed by those with an abnormal blood pressure response (hazard ratio, 3.19 [95% CI, 1.32–7.71]). Exercise-induced ischemia was also independently associated with lower SCD event-free survival (hazard ratio, 3.32 [95% CI, 1.27–8.70]). Exercise-induced ectopy was not associated with survival. Conclusions: Exercise abnormalities are common in childhood HCM. An abnormal exercise test result was independently associated with lower transplant-free survival, especially in those with an ischemic or abnormal blood pressure response with exercise. Exercise-induced ischemia was also independently associated with SCD events. These findings argue for routine exercise testing in childhood HCM as part of ongoing risk assessment.